A Randomized, Single‐Dose, Parallel‐Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1350 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Jie Cheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Omalizumab, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
This study evaluated the bioequivalence of omalizumab, a humanized monoclonal antibody against immunoglobulin‐E (IgE), with one of its biosimilar candidates. The study was designed as a randomized, double‐blind, parallel‐controlled trial. A total of subjects who met the inclusion criteria and did not meet the exclusion criteria were dynamically randomly assigned to receive the test drug or the reference drug with a single subcutaneous injection of 150 mg by the minimization method. The test group and the reference group had similar demographic characteristics and baseline characteristics of total IgE. The 90% confidence interval of the geometric average ratio of the area under the serum concentration–time curve from the time 0 to the time of last quantifiable concentration, the area under the serum concentration curve from time 0 to infinity, and the maximum observed serum concentration between the 2 groups were within 80%‐125%, showing bioequivalence. The changing trend of total and free IgE in the 2 groups was similar after administration, proving the pharmacodynamic similarity. The 2 groups had no significant difference in the positive rate of antidrug antibodies, and the total positive rate of neutralizing antibodies was 0. The incidence of treatment‐emergent adverse events and treatment‐related adverse events were similar between the 2 groups, with no serious adverse events. This study shows that the test drug had similar pharmacokinetics, immunogenicity, and safety to the reference omalizumab in healthy male subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
- Mabpharm Limited, Taizhou, China.
- State Key Laboratory of Antibody Medicine and Targeted Therapy, Shanghai, China.
- Shanghai Zhangjiang Biotechnology Co., Ltd, Shanghai, China.
- Shanghai Engineering Research Center of Phase I Clinical Research and Quality Consistency Evaluation for Drugs, Shanghai, China.
Zitieren
APA
Cheng, J., Wang, C., Xu, J., Zhao, C., Song, R., Wang, Y., Zou, Y., Zhang, X., Shan, Y., Zhou, J., & Jia, J. Y. (2024). A Randomized, Single‐Dose, Parallel‐Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1350
Vancouver
Cheng J, Wang C, Xu J, Zhao C, Song R, Wang Y, et al. A Randomized, Single‐Dose, Parallel‐Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1350
BibTeX
@article{Cheng2024,
author = {Cheng, Jie and Wang, Chenguang and Xu, Jin and Zhao, Chunyang and Song, Rong and Wang, Yijun and Zou, Yang and Zhang, Xunmin and Shan, Yong and Zhou, Jian and Jia, Jing-Ying},
title = {A Randomized, Single‐Dose, Parallel‐Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1350}
}
EUVIMED